Welcome to our dedicated page for OSR Holdings SEC filings (Ticker: OSRH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The OSR Holdings, Inc. (NASDAQ: OSRH) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. OSR Holdings is a global healthcare holding company engaged through its subsidiaries in immuno-oncology, regenerative biologics, and medical device technologies, and its filings offer detailed information on corporate transactions, governance, financing arrangements, and listing status.
Investors can review Form 8-K current reports where OSR Holdings describes material events such as share exchange agreements, licensing term sheets, financing amendments, and notices from The Nasdaq Stock Market LLC. For example, 8-K filings outline the Share Exchange Agreement under which OSR Holdings Co., Ltd. will acquire all issued and outstanding shares of Woori IO Co., Ltd., making Woori IO a wholly owned subsidiary, and describe Woori IO’s non-invasive biosensing technology for glucose monitoring. Other 8-Ks detail Vaximm AG’s non-binding and binding term sheets with BCM Europe AG for potential global licensing of the VXM01 oral cancer immunotherapy platform, including exclusivity periods and proposed financial structures.
The company’s proxy materials, such as the Definitive Proxy Statement on Schedule DEF 14A, set out proposals for director elections, advisory votes on executive compensation, share-based incentive plans under the 2025 Omnibus Incentive Plan, and approvals under Nasdaq Listing Rule 5635(d) for potential issuances of common stock or related securities in excess of 20% of outstanding shares. These documents also confirm OSR Holdings’ status as an emerging growth company and describe its principal executive offices and meeting logistics.
Filings also include disclosures related to Nasdaq listing compliance, such as the Form 8-K describing receipt of a minimum bid price deficiency notice under Listing Rule 5550(a)(2), along with the company’s stated intention to monitor its share price and consider options to regain compliance. Additional 8-Ks cover amendments to a Note Purchase Agreement and Common Stock Purchase Warrant with White Lion Capital, LLC, clarifying exchange caps and shareholder approval requirements.
On Stock Titan, these filings are supplemented by AI-powered summaries that highlight key terms, conditions, and implications for OSR Holdings’ capital structure and strategic direction. Users can quickly scan material agreements, governance proposals, and listing updates, and then drill down into the full-text filings for deeper analysis, including exhibits such as term sheets, annexes, and press releases incorporated by reference.
OSR Holdings, Inc. executive Kim Yeiseok, the Chief Operating Officer, filed an initial Form 3 reporting beneficial ownership of 24,699 shares of the company’s Common Stock. These shares are reported as held directly, and the filing does not show any recent purchase or sale transactions.
OSR Holdings, Inc. entered into a second amendment to its equity line with White Lion GBM Innovation Fund, adding new intraday and fixed purchase mechanisms that let the company sell stock at 90% of the volume-weighted average price over defined trading periods, with threshold-price protections for certain purchases.
The company also agreed to issue a senior secured convertible promissory note with a principal amount of $1,055,555.55 to White Lion. OSR Holdings received $500,000 in cash and reduced approximately $2,019,290 of amounts outstanding under an existing warrant, effectively cancelling that warrant.
The note bears 5% annual interest, matures in nine months, and is initially convertible at the holder’s option at a $1.00 per share fixed price, with certain market-based conversion alternatives. Conversion generally cannot begin until six months after issuance and is limited by a 4.99% beneficial ownership cap, which White Lion may increase to 9.99%. The note is a senior secured obligation, backed by substantially all company assets, and was issued in a private placement relying on Securities Act exemptions.
OSR Holdings, Inc. filed an amended current report to correct an exhibit attached to a prior disclosure. The amendment replaces Exhibit 10.1 with a corrected version of the Global License Agreement for VXM01, dated March 23, 2026, among Vaximm AG, OSR Holdings, Inc. and BCM Europe AG. The update is described as fixing clerical errors, including the stated per share price, and does not change any other information contained in the original report.
OSR Holdings, Inc. entered into a binding term sheet with BCM Europe AG for a revised global exclusive license of VXM01, with OSR Holdings added as a direct counterparty and primary recipient of economics.
Upon a definitive license agreement, Vaximm AG will grant BCME an exclusive, worldwide, sublicensable license to develop and commercialize VXM01. BCME will be responsible for up to $815.0 million in milestone payments payable directly to OSR Holdings, while OSR Holdings will provide Vaximm with a development financing facility of up to $30.0 million. Closing of a definitive agreement is subject to due diligence, board approvals, and an independent fairness opinion.
OSR Holdings, Inc., formerly Bellevue Life Sciences Acquisition Corp., is now a global healthcare holding company following its February 14, 2025 business combination with Korea-based OSR Holdings Co., Ltd. The company focuses on acquiring and developing innovative pharma and medical device businesses.
Its three wholly owned subsidiaries are: Vaximm, which develops oral T‑cell immunotherapies including VXM01 for glioblastoma and pancreatic cancer with orphan drug designations; Darnatein, which designs biologics for bone and cartilage regeneration; and RMC, a Korean neurovascular device distributor being transformed into a healthcare 4PL logistics platform.
As of December 31, 2025, non‑affiliate equity value was about $7.7 million based on a $0.56 share price, and there were 33,124,755 common shares outstanding as of March 20, 2026. The filing highlights extensive patent portfolios and early- to mid‑stage clinical data but also significant development, financing and market risks.
OSR Holdings, Inc. furnished an update to ensure fair disclosure after inadvertently sharing non‑public information with a sell‑side analyst about its drug development subsidiary, Vaximm AG, and SillaJen, Inc.
Vaximm is in active, but non‑binding, negotiations with SillaJen over a potential licensing arrangement for Pexa‑Vec, an oncolytic immunotherapy in a Phase 2 FDA‑regulated study for renal cell carcinoma. Separately, OSR Holdings’ management has held very early, exploratory verbal discussions about potentially acquiring a controlling interest in SillaJen representing approximately 16% of its outstanding common shares. No term sheet, structure, financing, or definitive agreements exist for either the licensing or equity transaction, and the company stresses there is no assurance any deal will be completed. OSR Holdings indicates it does not plan further updates unless later developments independently require disclosure.
OSR Holdings, Inc. received notice from Nasdaq that it has been granted an additional 180-day period, until August 31, 2026, to regain compliance with the Nasdaq minimum bid price rule requiring a bid of at least $1.00 per share.
The company was first notified on September 5, 2025, that its stock had traded below $1.00 for 30 consecutive business days and initially had until March 4, 2026, to regain compliance. Nasdaq granted more time because OSR Holdings meets all other Nasdaq Capital Market listing standards, including market value of publicly held shares.
If the closing bid price is at least $1.00 per share for a minimum of 10 consecutive business days during this new period, Nasdaq will confirm that the company has regained compliance. OSR Holdings plans to monitor its share price and consider available options to meet Nasdaq’s bid price requirement.
OSR Holdings, Inc. completed the acquisition of South Korea-based medical device company Woori IO Co., Ltd. (WORIO) on January 26, 2026 through a share exchange under the Korean Commercial Act. OSR Holdings’ subsidiary OSR Holdings Co., Ltd. (OSRK) acquired all issued and outstanding WORIO shares, making WORIO a wholly owned subsidiary of OSRK and an indirect subsidiary of OSR Holdings.
Each WORIO share was exchanged for 0.948832 OSRK shares, and OSRK issued an aggregate of 84,338 new shares in exchange for 88,891 WORIO shares. The transaction was completed using equity in the subsidiary, and no OSR Holdings common stock was issued. OSR Holdings plans to file any required financial statements for this acquisition by amendment within 71 days.
OSR Holdings, Inc. reported that its wholly owned subsidiary Vaximm AG signed a binding term sheet with BCM Europe AG for a proposed global exclusive license of the VXM01 oral cancer immunotherapy platform. Under the term sheet, once a definitive global license agreement is executed, BCM Europe AG would pay Vaximm an upfront payment of $30.0 million, split between $15.0 million in cash and $15.0 million in digital assets, plus up to $815.0 million in potential clinical, regulatory, and commercial milestone payments.
The term sheet includes binding provisions on the license grant, financial terms, and exclusivity, while the final agreement is still subject to customary conditions, including an independent third-party fairness opinion. The company also furnished a press release describing the binding term sheet and the proposed VXM01 license arrangement.
OSR Holdings, Inc. (OSRH) reported that its Swiss-based subsidiary, Vaximm AG, has signed a non-binding global license agreement term sheet with BCM Europe AG, the company’s largest shareholder. The term sheet covers the potential global license of Vaximm’s VXM01 oral cancer immunotherapy platform and includes an exclusivity period for negotiations and certain binding provisions.
According to the related press release, the contemplated license could provide $20 million upfront and up to $815 million in milestone payments, if a definitive agreement is ultimately signed and completed. The current term sheet itself is not a final contract and does not yet impose material obligations on OSR Holdings.